Skip to Content

Join the 'Alectinib' group to help and get support from people like you.

Alectinib News

U.S. Pays Highest Prices for Cancer Meds: Study

Posted 6 Jun 2016 by Drugs.com

MONDAY, June 6, 2016 – The United States pays the highest prices in the world for generic and brand-name cancer drugs, a new study has found. However, as the world's wealthiest nation, the United States is better able to pay for those pricey drugs than poorer countries with somewhat lower medication prices, added study lead author Dr. Daniel Goldstein. People in China and India are much less able to afford cancer drugs than Americans, he said, even though U.S. monthly drug prices are about three to six times higher in the United States. That doesn't mean America came out on top in overall drug affordability, however. Developed nations such as Australia, England and Israel had the "best deal" in the world on cancer drugs, thanks to government programs that regulate drug pricing, the study found. "America is the wealthiest nation, but its drug prices are significantly higher – so much ... Read more

Related support groups: Cancer, Provera, Depo-Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Tamoxifen, Medroxyprogesterone, Arimidex, Tretinoin, Fluorouracil, Lupron Depot, Femara, Gleevec, Lung Cancer, Colorectal Cancer, Isotretinoin, Rituxan, Claravis

Alecensa Approved for Lung Cancer Tied to Gene Mutation

Posted 21 Dec 2015 by Drugs.com

FRIDAY, Dec. 11, 2015 – Alecensa (alectinib) has been approved by the U.S. Food and Drug administration to treat anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer, the agency said Friday in a news release. This type of cancer often spreads to the brain. The pill is sanctioned for instances of worsening disease after patients take a standard therapy called Xalkori (crizotinib), or if they are unable to tolerate Xalkori. More than 221,000 people in the United States are projected to develop lung cancer this year, and more than 158,000 will die from it, according to the National Cancer Institute. ALK gene mutations are involved in about 5 percent of cases of non-small cell lung cancer, the FDA said. Alecensa is designed to block the effects of the ALK protein, thereby preventing these cancer cells from growing and spreading. The most common side effects of the drug are ... Read more

Related support groups: Non-Small Cell Lung Cancer, Alectinib, Alecensa

FDA Approves Alecensa (alectinib) for ALK-Positive Non-Small Cell Lung Cancer

Posted 12 Dec 2015 by Drugs.com

December 11, 2015 – The U.S. Food and Drug Administration today approved Alecensa (alectinib) to treat people with advanced (metastatic) ALK-positive non-small cell lung cancer (NSCLC) whose disease has worsened after, or who could not tolerate treatment with, another therapy called Xalkori (crizotinib). Lung cancer is the leading cause of cancer death in the United States, with an estimated 221,200 new diagnoses and 158,040 deaths in 2015, according to the National Cancer Institute. An ALK (anaplastic lymphoma kinase) gene mutation can occur in several different types of cancer cells, including lung cancer cells. ALK gene mutations are present in about 5 percent of patients with NSCLC. In metastatic cancer, the disease spreads to new parts of the body. In ALK-positive NSCLC metastatic patients, the brain is a common place for the disease to spread. “Today’s approval provides a new th ... Read more

Related support groups: Non-Small Cell Lung Cancer, Alectinib, Alecensa

Ask a Question

Further Information

Related Condition Support Groups

Non-Small Cell Lung Cancer

Related Drug Support Groups

Alecensa

Alectinib Patient Information at Drugs.com